An Early Phase 1 interventional study of Flortaucipir F18 and Brain PET Scan in Alzheimer Disease, sponsored by Avid Radiopharmaceuticals. Completed at 2 sites in United States. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Early Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 14th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 1, and was the 20th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 20 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 3 started in 2013.
This study's enrollment of 36 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 70th largest by enrollment of the 95 interventional ones that give a count, is one of 7 that started in 2013, is one of 34 in phase 1, and was the 76th registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
This early phase 1 study explored the brain uptake, retention, and safety of flortaucipir and obtained preliminary information regarding dosimetry of flortaucipir.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receiving a brain PET scan after flortaucipir administration
Drug: Flortaucipir F18 · Procedure: Brain PET Scan · Drug: Florbetapir F 18 · Procedure: Brain MRI
Subjects receiving a whole body PET scan after flortaucipir administration
Drug: Flortaucipir F18 · Procedure: Whole body PET scan
Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)
Procedure: Brain PET Scan · Drug: Florbetapir F 18 · Procedure: Brain MRI
IV injection, 370 MBq (10 mCi), single dose
Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid
positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
IV injection, 370 MBq (10 mCi), single dose
Also known as: Amyvid
Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
Brain Flortaucipir Uptake
Brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVr), normalized to the entire cerebellum. A global cortical average volume of interest (VOI) is the average SUVr of the occipital cortex, parietal cortex, and temporal cortex. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: 80-100 minutes postdose
Flortaucipir Whole Body Effective Dose
Radiation dose estimates measured in millisieverts per megabecquerel (mSv/MBq) for the whole body obtained from Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM) radiation dosimetry code. Results calculated using 73.7-kg man model.
Time frame: injection to 6 hours postdose
Flortaucipir PET Correlations With Cognitive Assessments (Mini-mental State Exam)
Spearman's correlations between flortaucipir SUVr and cognitive function as measured on the Mini-Mental State Examination (MMSE). MMSE is a 30-point questionnaire that is used to measure cognitive impairment. 0 is the lowest score and 30 is the highest score, indicating normal cognitive function. Lower MMSE scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.
Time frame: at baseline
Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Digit Symbol Substitution Test)
Spearman's correlations between flortaucipir SUVr and cognitive function as measured on Digit Symbol Substitution Test (DSST). The DSST is sensitive to the presence of cognitive dysfunction as well as to change in cognitive function. Scores range from 0 to 133. Lower DSST scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.
Time frame: at baseline
Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Alzheimer's Disease Assessment Scale)
Spearman's correlations between flortaucipir SUVr and cognitive function as measured on a Modified Alzheimer's Disease Assessment Scale (ADAS)-Cognitive subscale (including orientation, verbal memory, language, and praxis, minus the spoken language assessment). Scores on the modified scale can range from 0 to 65. Higher scores indicate worsening cognitive function. For this analysis, positive correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and negative correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.
Time frame: at baseline
Enrollment occurred between Aug and Dec 2013. Subjects in the MRI and Amyloid Extension cohort received flortaucipir brain PET scans in Study T807000 (NCT01733355)
| Milestone | Brain PET Scan (AD Subjects) | Brain PET (MCI Subjects) | Brain PET (YCN Subjects) | Brain PET (OCN Subjects) | Whole Body PET Scan | MRI and Amyloid Extension Cohort |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 5 | 4 | 13 | 7 |
| Flortaucipir pet scan | 4 | 3 | 4 | 4 | 9 | 0 |
| Florbetapir pet scan | 4 | 3 | 0 | 4 | 0 | 4 |
| Completed | 4 | 3 | 4 | 4 | 9 | 7 |
| Not completed | 0 | 0 | 1 | 0 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 3 | 0 |
Brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVr), normalized to the entire cerebellum. A global cortical average volume of interest (VOI) is the average SUVr of the occipital cortex, parietal cortex, and temporal cortex. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Brain PET Scan (AD Subjects) | Brain PET (MCI Subjects) | Brain PET (YCN Subjects) | Brain PET (OCN Subjects) |
|---|---|---|---|---|
| Brain Flortaucipir Uptake | 1.780 ± 0.857 | 1.317 ± 0.161 | 1.128 ± 0.047 | 1.107 ± 0.175 |
Radiation dose estimates measured in millisieverts per megabecquerel (mSv/MBq) for the whole body obtained from Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM) radiation dosimetry code. Results calculated using 73.7-kg man model.
| mSv/MBq | Whole Body Flortaucipir PET Scan |
|---|---|
| Flortaucipir Whole Body Effective Dose | 0.0241 ± 0.00160 |
Spearman's correlations between flortaucipir SUVr and cognitive function as measured on the Mini-Mental State Examination (MMSE). MMSE is a 30-point questionnaire that is used to measure cognitive impairment. 0 is the lowest score and 30 is the highest score, indicating normal cognitive function. Lower MMSE scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.
| correlation coefficient | All Subjects/Brain PET |
|---|---|
| Flortaucipir PET Correlations With Cognitive Assessments (Mini-mental State Exam) | -0.404 (-0.706 to 0.044) |
Spearman's correlations between flortaucipir SUVr and cognitive function as measured on Digit Symbol Substitution Test (DSST). The DSST is sensitive to the presence of cognitive dysfunction as well as to change in cognitive function. Scores range from 0 to 133. Lower DSST scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.
| correlation coefficient | All Subjects/Brain PET |
|---|---|
| Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Digit Symbol Substitution Test) | -0.273 (-0.744 to 0.403) |
Spearman's correlations between flortaucipir SUVr and cognitive function as measured on a Modified Alzheimer's Disease Assessment Scale (ADAS)-Cognitive subscale (including orientation, verbal memory, language, and praxis, minus the spoken language assessment). Scores on the modified scale can range from 0 to 65. Higher scores indicate worsening cognitive function. For this analysis, positive correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and negative correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.
| correlation coefficient | All Subjects/Brain PET |
|---|---|
| Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Alzheimer's Disease Assessment Scale) | 0.220 (-0.447 to 0.719) |
Radiation dose estimates measured in millisieverts per megabecquerel (mSv/MBq) for the whole body obtained from Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM) radiation dosimetry code. Results calculated using 73.7-kg man model and accounting for total integrated radioactivity excreted in the urine collected in Study A15 (NCT02336360)
| mSv/MBq | Whole Body Flortaucipir PET Scan |
|---|---|
| Flortaucipir Whole Body Effective Dose With Urine Radioactivity | 0.0235 ± 0.0016 |
Collected over End of study for AE reporting was 48 hours after the last study drug administration.. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brain PET Scan (AD Subjects) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Brain PET (MCI Subjects) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Brain PET (YCN Subjects) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Brain PET (OCN Subjects) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Whole Body PET Scan | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| MRI and Amyloid Extension Cohort | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Event | Brain PET Scan (AD Subjects) | Brain PET (MCI Subjects) | Brain PET (YCN Subjects) | Brain PET (OCN Subjects) | Whole Body PET Scan | MRI and Amyloid Extension Cohort |
|---|---|---|---|---|---|---|
| diarrhoeaGastrointestinal disorders | 0/4 | 0/3 | 1/4 | 0/4 | 0/9 | 0/4 |
| headacheNervous system disorders | 0/4 | 0/3 | 0/4 | 0/4 | 2/9 | 0/4 |
| musculoskeletal discomfortMusculoskeletal and connective tissue disorders | 0/4 | 0/3 | 0/4 | 0/4 | 1/9 | 0/4 |
Baseline demographics analysis includes subjects receiving a florbetapir or a flortaucipir PET scan in the study.
| Age, Continuous(years) | Brain PET Scan (AD Subjects) | Brain PET (MCI Subjects) | Brain PET (YCN Subjects) | Brain PET (OCN Subjects) | Whole Body PET Scan | MRI and Amyloid Extension Cohort | Total |
|---|---|---|---|---|---|---|---|
| Mean | 68.0 ± 7.87 | 78.7 ± 2.89 | 27.5 ± 2.08 | 66.3 ± 0.50 | 56.3 ± 4.42 | 73.0 ± 13.09 | 60.1 ± 16.52 |
| Sex/Gender, Customized(Participants) | Brain PET Scan (AD Subjects) | Brain PET (MCI Subjects) | Brain PET (YCN Subjects) | Brain PET (OCN Subjects) | Whole Body PET Scan | MRI and Amyloid Extension Cohort | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 3 | 3 | 1 | 11 |
| Male | 2 | 2 | 3 | 1 | 6 | 2 | 16 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Brain PET Scan (AD Subjects) | Brain PET (MCI Subjects) | Brain PET (YCN Subjects) | Brain PET (OCN Subjects) | Whole Body PET Scan | MRI and Amyloid Extension Cohort | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 4 | 1 | 3 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 4 | 3 | 0 | 3 | 5 | 3 | 18 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Brain PET Scan (AD Subjects) | Brain PET (MCI Subjects) | Brain PET (YCN Subjects) | Brain PET (OCN Subjects) | Whole Body PET Scan | MRI and Amyloid Extension Cohort | Total |
|---|---|---|---|---|---|---|---|
| United States | 4 | 3 | 4 | 4 | 9 | 4 | 28 |
Ran from Aug 2013 to primary completion in Dec 2013, 3 months.
Results were first posted in Sep 2020, 6 years 9 months after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 3 months is below that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Flortaucipir · Florbetapir